| Patents for A61K 38 - Medicinal preparations containing peptides (316,240) |
|---|
| 09/16/2004 | WO2004050846A8 Wall teichoic acid as a target for anti-staphylococcal therapies and vaccines |
| 09/16/2004 | WO2004050706A3 Regulatory t-cells |
| 09/16/2004 | WO2004050679A3 Mutant glycoproteins |
| 09/16/2004 | WO2004050096A3 Phosphoantigens for regulating an immune response |
| 09/16/2004 | WO2004048409A3 Mutants of the tumor necrosis factor alpha with deletion of n-terminal amino acids |
| 09/16/2004 | WO2004047762A3 Methods for treating cancer using porimin as a target |
| 09/16/2004 | WO2004047731A8 Modulation of notch3 expression |
| 09/16/2004 | WO2004046376A3 Methods and kits for diagnosing and treating b-cell chronic lymphocytic leukemia (b-cll) |
| 09/16/2004 | WO2004046180A3 Chemosensitization by a non-apoptogenic heat shock protein 70-binding apoptosis inducing factor mutant add70 |
| 09/16/2004 | WO2004041205A3 Ha4, a new osteoblast- and chondrocyte-specific small secreted peptide, compositions and methods of use |
| 09/16/2004 | WO2004038021A8 Gpr54 knock-out mammals and screening methods using them |
| 09/16/2004 | WO2004033482A3 Phenolic binding peptides |
| 09/16/2004 | WO2004029213A3 Compositions and methods for delivery of short interfering rna and short hairpin rna |
| 09/16/2004 | WO2004026905A3 Transporter/channel proteins |
| 09/16/2004 | WO2004026264A3 Novel aromatic compounds possessing antifungal or antibacterial activity |
| 09/16/2004 | WO2004025263A3 Protein and peptide expression for passive immunity |
| 09/16/2004 | WO2004022577A3 Long acting erythropoietins that maintain tissue protective activity of endogenous erythropoietin |
| 09/16/2004 | WO2004016230A3 Identification of the endothelial receptor for the angiostatin kringle-5 |
| 09/16/2004 | WO2004006862A3 A method for the modulation of angiogenesis |
| 09/16/2004 | WO2003102160A3 Rationally designed polysaccharide lyases derived from chondroitinase b |
| 09/16/2004 | WO2003099778A3 Inhibitors of proteins from the rho-gef family |
| 09/16/2004 | WO2003090682A3 Treatment and prevention of pulmonary conditions |
| 09/16/2004 | WO2003088918A3 PHARMACEUTICAL COMPOSITIONS CONTAINING α3β4 NICOTINIC RECEPTOR ANTAGONISTS AND METHODS OF THEIR USE |
| 09/16/2004 | WO2003088898A3 Compositions and methods for the diagnosis and treatment of tumor |
| 09/16/2004 | WO2003084466A3 FACTORVIIa COMPOSITIONS |
| 09/16/2004 | WO2003083079A3 Bone generation by gene therapy |
| 09/16/2004 | WO2003070746A3 Purification and characterization of a prothrombin activator from the bristled of lonomia obliqua |
| 09/16/2004 | WO2003062265A3 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus |
| 09/16/2004 | WO2003060097A3 USE OF SOLUBLE Ϝδ T CELL RECEPTORS FOR REGULATING T CELL FUNCTION |
| 09/16/2004 | WO2003053457A8 Polypeptide, the conjugate thereof containing doxorubicine and a pharmaceutical composition based thereon |
| 09/16/2004 | WO2003052048A3 Nucleic acid-associated proteins |
| 09/16/2004 | WO2003050244A3 Antisense modulation of g protein-coupled receptor etbr-lp-2 expression |
| 09/16/2004 | WO2003045318A3 Manipulation of cytokine levels using cd83 gene products |
| 09/16/2004 | WO2003045228A9 Methods for treating autoimmune disorders, and reagents related thereto |
| 09/16/2004 | WO2003043583A3 Treatment of immunological disorders using anti-cd30 antibodies |
| 09/16/2004 | WO2003040307A3 Heteromultimeric tnf ligand family members |
| 09/16/2004 | WO2003033668A3 Correlation of gene expression with chromosome abnormalities in ataxia telangiectasia tumorigenesis |
| 09/16/2004 | WO2002100827A3 Method for increasing the survival of dopamine secreting cells |
| 09/16/2004 | WO2002050097A3 Anti-allergic complex molecules |
| 09/16/2004 | US20040181821 expression cassettes, efficiently introduced into cultured mammalian cells; allows user to evaluate the transfection and siRNA synthetic efficiency |
| 09/16/2004 | US20040181073 Amides, useful in the inhibition of il-8-induced chemotaxis of neutrophils |
| 09/16/2004 | US20040181047 33 human secreted proteins |
| 09/16/2004 | US20040181044 for bone marrow recovery in treatment of radiation, chemical, or chemotherapeutic induced bone marrow aplasia or myelosuppression |
| 09/16/2004 | US20040181041 Fusion protein capable of inducing programmed cell death for use in treatment cell proliferative diseases and infection |
| 09/16/2004 | US20040181037 Phosphatidyl serine receptors and uses thereof |
| 09/16/2004 | US20040181035 Modified colony stimulating factor for treatment of hematopoietic disorder |
| 09/16/2004 | US20040181034 Multimeric Apo A-I agonist compounds |
| 09/16/2004 | US20040181033 Binding agents which inhibit myostatin |
| 09/16/2004 | US20040181032 for promoting the release of growth hormone and of enhancing wound healing in a human or animal subject; for treating short stature, cachexia, wasting, type 2 diabetes, and poor circulation |
| 09/16/2004 | US20040180848 Method of killing cancer cells |
| 09/16/2004 | US20040180846 Connexin enhances chemotherapy-induced apoptiosis in human cancer cells inhibiting tumor cell proliferation |
| 09/16/2004 | US20040180844 Method of killing cancer cells |
| 09/16/2004 | US20040180836 Blocking peptide for inflammatory cell secretion |
| 09/16/2004 | US20040180835 Use of the protein uk114 or of fragments thereof for the treatment and prevention of the endotoxic shock |
| 09/16/2004 | US20040180834 Methods for manipulating upper gastrointestinal transit, blood flow, and satiety, and for treating visceral hyperalgesia |
| 09/16/2004 | US20040180833 Treating metabolic syndrome; reducing abdominal/visceral obesity, insulin resistance, lipoprotein aberrations and/or hypertension; noninsulin dependent diabetes mellitus |
| 09/16/2004 | US20040180832 Sustained peptide-release formulation |
| 09/16/2004 | US20040180831 Efficiently lower serum calcium levels, bioavailability; chymotrypsin and/or trypsin degradation resistance; bone disorders |
| 09/16/2004 | US20040180830 Methods and compositions for preventing and treating male erectile dysfunction and female sexual arousal disorder |
| 09/16/2004 | US20040180829 Compounds and methods for regulating bacterial growth and pathogenesis |
| 09/16/2004 | US20040180828 Apoptosis suppression; polypeptides of sequence 2 having surface groove including amino acid residues P325, G326, H343 and L344 |
| 09/16/2004 | US20040180827 Stabilized lyophilized compositions comprising tissue factor pathway inhibitor or tissue factor pathway inhibitor variants |
| 09/16/2004 | US20040180826 Novel receptor that causes cell death |
| 09/16/2004 | US20040180825 Semaphorin polypeptides |
| 09/16/2004 | US20040180824 Combination treatment using exendins and thiazolidinediones |
| 09/16/2004 | US20040180823 Peptides, peptidomimetics; promoting programmed cell death; neural regeneration |
| 09/16/2004 | US20040180822 Pretreating prior to insertion during tissue repair surgery; promoting healing |
| 09/16/2004 | US20040180821 Treatment of congestive heart failure |
| 09/16/2004 | US20040180820 Spontaneous resorption of herniated disc; inducing vascular tubule formation using angiogenesis inducing substance |
| 09/16/2004 | US20040180818 adiponectin (adipose specific protein); suppressing fibrosis during regrowth; inhibiting TGFB and PDGF action on hepatic stellate cells; cirrhosis repair |
| 09/16/2004 | US20040180817 Use of tumor necrosis factor alpha p75 receptor antagonist or endothelin receptor antagonist, converting enzyme inhibitor or neutralizing agent; reducting cerebral perfusion; method of identifying candidates |
| 09/16/2004 | US20040180816 Combination comprising a p-gp inhibitor and an anti-epileptic drug |
| 09/16/2004 | US20040180815 Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors |
| 09/16/2004 | US20040180814 N-acylated prolinol derivatives; deesterification; Gram-positive bacteria |
| 09/16/2004 | US20040180813 4-Amino acid functionalized-2-pyrophosphatyl-pyranes; direct assay, high throughput screening for enzyme inhibitors; N-acetylglucosaminyltransferase |
| 09/16/2004 | US20040180811 Compositions involving M-RIP, and related methods for screening for anti-hypertensive agents, and uses thereof |
| 09/16/2004 | US20040180808 Multiple sclerosis; molecules related to 21.5 kDa fetal isoform; inducing selective T cell apoptosis; kits |
| 09/16/2004 | US20040180434 Materials and methods for nerve grafting, selection of nerve grafts, and in vitro nerve tissue culture |
| 09/16/2004 | US20040180433 Methods of using mammalian RNase H and compositions thereof |
| 09/16/2004 | US20040180419 by combining protein replacement therapy with active site-specific chaperones (ASSC) to increase the stability and efficiency of the protein being administered |
| 09/16/2004 | US20040180418 Candida kefyr cytosine deaminase |
| 09/16/2004 | US20040180417 Secretase/sheddase with asp-ase activity on the beta-site app-cleaving enzyme (bace, asp2, memepsin2) |
| 09/16/2004 | US20040180407 Novel G protein coupled receptor protein, DNA and its ligand |
| 09/16/2004 | US20040180405 Novel potassium channels and genes encoding these potassium channels |
| 09/16/2004 | US20040180402 Isolated human ras-like proteins, nucleic acid molecules encoding these human ras-like proteins, and uses thereof |
| 09/16/2004 | US20040180389 antigen bearing target and a fusion polypeptide which can bind to a cell surface binding moiety (e.g., a carbohydrate) and serve as a ligand for a cell surface polypeptide; immunotherapy; e.g. fusion protein of a lectin and a ligand of a cell surface receptor of an antigen presenting cell |
| 09/16/2004 | US20040180386 Using major histocompatibility complex polypeptides as tools in identifying lymphocyte binding sites; immunosuppression and tumor therapeutics |
| 09/16/2004 | US20040180371 Nucleotide sequences coding novel serine protease for identifying modulator for diagnosis, treatment and prevention of cell proliferative disorders |
| 09/16/2004 | US20040180357 Compositions and methods for siRNA inhibition of HIF-1 alpha |
| 09/16/2004 | US20040180354 Comprises polypeptides which are displayable on antigen presenting cells of immune system for use in prevention and treatment of infection and vaccine development; immunotherapy |
| 09/16/2004 | US20040180353 Methods of assaying for cell cycle modulators using components of the ubiquitin ligation cascade |
| 09/16/2004 | US20040180351 Interfering RNA molecules |
| 09/16/2004 | US20040180341 Transcriptional regulation of kinase inhibitors |
| 09/16/2004 | US20040180338 Mutated eukariotic transalation initiation factor 2 alpha kinase3, eif2ak3, in patients with neonatal insuluin-dependant diabetes and multiple epiphyseal dyslapsia (wolcott-rallison syndrome) |
| 09/16/2004 | US20040180102 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 09/16/2004 | US20040180097 For encapsulating an unstable drug and/or a drug with unpleasant taste, drug entrapped in pores of grains |
| 09/16/2004 | US20040180091 Carbonated hydroxyapatite-based microspherical composites for biomedical uses |
| 09/16/2004 | US20040180065 Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
| 09/16/2004 | US20040180063 Vaccination with peptide of MHC class ll molecules for treatment of autoimmune disease |
| 09/16/2004 | US20040180061 Botulinum toxin therapy for neuropsychiatric disorders |